# Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

> **NCT00553683** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer
- Colorectal Cancer
- Gastric Cancer
- Liver Cancer
- Melanoma (Skin)
- Metastatic Cancer
- Ovarian Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** poly ICLC
- **PROCEDURE:** hepatic artery embolization
- **RADIATION:** 3-dimensional conformal radiation therapy

## Key facts

- **NCT ID:** NCT00553683
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553683, "Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00553683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*